Table 3 Characteristics of hospital admission prior to home treatment and monitoring
Median value or n/N | Q1-Q3 or % | |
|---|---|---|
Duration of hospital admission, days | 6 | 4 – 18 |
Admitted in the Intensive Care Unit | 3/19 | 16% |
Highest C-reactive protein during admission | 104 | 72 – 180 |
Highest level of Ferritin during admission | 1410 | 603 – 1793 |
Drugs received for COVID-19 | ||
Systemic corticosteroids | 19/19 | 100% |
Tocilizumab | 5/19 | 26% |
Nirmatrelvir/ritonavir | 1/19 | 5% |
Other antiviral medication | 0/19 | 0% |
Low-molecular weight heparin | 17/19 | 89% |
Maximum ventilation support received | ||
Low-flow nasal oxygen supplement | 12/19 | 63% |
Non-invasive ventilation | 5/19 | 26% |
Invasive mechanical ventilation | 2/19 | 11% |
Complications | ||
Clostridioides difficile infection | 1/19 | 5% |
Other bacterial infections | ||
Serratia marcescens lower respiratory tract infection | 1/19 | 5% |